PepTivator® EBV BZLF1

PepTivator® EBV BZLF1 is a peptide pool that consists mainly of 15-mer peptides with 11 amino acid (aa) overlap, covering the complete sequence of the Epstein-Barr virus BZLF1 protein (UniProt ID: P03206).

PepTivator peptide pools have been developed for the efficient in vitro stimulation of antigen–specific CD4+ and CD8+ T cells as peptides of 15-aa length with 11-aa overlap represent an optimized solution for stimulating both CD4+ and CD8+ T cells in various applications.1

Quantitative, phenotypical, or f

... read more
Choose your product:

Related products for PepTivator® EBV BZLF1

Product data and images for PepTivator® EBV BZLF1
Figure 1

Production of IFN-γ by human CD4+ or CD8+ T cells after stimulation with different antigens using PepTivator Peptide Pools. Data from two different donors are shown (triplicates).

Specifications for PepTivator® EBV BZLF1
Overview

PepTivator® EBV BZLF1 is a peptide pool that consists mainly of 15-mer peptides with 11 amino acid (aa) overlap, covering the complete sequence of the Epstein-Barr virus BZLF1 protein (UniProt ID: P03206).

PepTivator peptide pools have been developed for the efficient in vitro stimulation of antigen–specific CD4+ and CD8+ T cells as peptides of 15-aa length with 11-aa overlap represent an optimized solution for stimulating both CD4+ and CD8+ T cells in various applications.1

Quantitative, phenotypical, or functional analysis of EBV BZLF1–specific T cell immunity can provide important information on the natural course of immune responses in healthy or immunocompromised individuals.

Detailed product information
Background information

Epstein-Barr virus (EBV) is a human γ-herpesvirus with B cell growth–transforming ability and lymphomagenic potential. More than 90% of human adults are infected with EBV. Usually the primary infection is asymptomatic, but some individuals develop an infectious mononucleosis, a self-limiting lymphoproliferative disease. BZLF1 activates a promoter of an EBV gene and plays a key role in the switch from latent to productive infection of EBV. BZLF1-specific CD4+ and CD8+ T cells have been found in EBV-infected individuals.2–4

Downstream applications

The in vitro stimulation of EBV BZLF1–specific CD4+ and CD8+ T cells with PepTivator EBV BZLF1 causes the secretion of effector cytokines and the upregulation of activation markers, which then allow the detection and isolation of EBV BZLF1–specific T cells 5:

  • Detection and analysis of EBV BZLF1–specific CD4+ and CD8+ effector/memory T cells in PBMCs by MACS® Cytokine Secretion Assays, intracellular cytokine staining, or other technologies.
  • Isolation of viable EBV BZLF1–specific CD4+ T cells with the CD154 MicroBead Kit, or of CD4+ and CD8+ T cells using the CD137 MicroBead Kit or MACS Cytokine Secretion Assay – Cell Enrichment and Detection Kits. Subsequently, cells can be expanded for generation of T cell lines.
  • Generation of EBV BZLF1–specific CD4+ and CD8+ effector/memory T cells from naive T cell populations for research on immunotherapy and vaccination.
  • Pulsing of antigen-presenting cells, for example, for research on dendritic cell vaccination.
Resources for PepTivator® EBV BZLF1
Citations for PepTivator® EBV BZLF1
Publications
  1. Kiecker, F. et al. (2004) Analysis of antigen-specific T-cell responses with synthetic peptides--what kind of peptide for which purpose? Hum Immunol 65: 523-536
  2. Dodero, A. et al. (2009) Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. Blood 113: 4771-4779
  3. Tynan, F. E. et al. (2005) The immunogenicity of a viral cytotoxic T cell epitope is controlled by its MHC-bound conformation. J. Exp. Med. 202: 1249-1260
  4. Precopio, M. L. et al. (2003) Differential kinetics and specificity of EBV-specific CD4+ and CD8+ T cells during primary infection. J Immunol 170: 2590-2598
  5. Saulquin, X. et al. (2000) A global appraisal of immunodominant CD8 T cell responses to Epstein-Barr virus and cytomegalovirus by bulk screening. Eur. J. Immunol. 30: 2531-2539

You have previously chosen International as your location.
What do you want to do?